Q-omics provides the consensus-scored LAMP5 profile across patient tissues and cancer cell-line models. LAMP5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LAMP5 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LAMP5 RNA expression shows 19,943 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, HNSC, and BRCA as cancer lineages where LAMP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAMP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAMP5 survival associations across molecular data types. LAMP5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAMP5 RNA expression–survival associations across cancer types. High LAMP5 expression shows unfavorable associations in STAD, KIRP, KIRC, UVM and ACC, but favorable associations in CESC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for LAMP5 RNA expression.
This table summarizes LAMP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for LAMP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAMP5 shows higher tumor expression in HNSC, THCA, BRCA, LUAD, BLCA and LUSC. The HNSC box plot shows higher LAMP5 RNA expression in tumor versus normal tissue (log2 FC = +2.624, t-test p < 0.001).
This table shows molecular features associated with LAMP5 in patient tissues and cancer cell lines. In patient samples, LAMP5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LAMP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
